Literature DB >> 3616518

The positive and negative syndrome scale (PANSS) for schizophrenia.

S R Kay, A Fiszbein, L A Opler.   

Abstract

The variable results of positive-negative research with schizophrenics underscore the importance of well-characterized, standardized measurement techniques. We report on the development and initial standardization of the Positive and Negative Syndrome Scale (PANSS) for typological and dimensional assessment. Based on two established psychiatric rating systems, the 30-item PANSS was conceived as an operationalized, drug-sensitive instrument that provides balanced representation of positive and negative symptoms and gauges their relationship to one another and to global psychopathology. It thus constitutes four scales measuring positive and negative syndromes, their differential, and general severity of illness. Study of 101 schizophrenics found the four scales to be normally distributed and supported their reliability and stability. Positive and negative scores were inversely correlated once their common association with general psychopathology was extracted, suggesting that they represent mutually exclusive constructs. Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.

Entities:  

Mesh:

Year:  1987        PMID: 3616518     DOI: 10.1093/schbul/13.2.261

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  2000 in total

1.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Authors:  A Abi-Dargham; J Rodenhiser; D Printz; Y Zea-Ponce; R Gil; L S Kegeles; R Weiss; T B Cooper; J J Mann; R L Van Heertum; J M Gorman; M Laruelle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 2.  Recent advances in the genetics of schizophrenia.

Authors:  D M Waterwort; A S Bassett; L M Brzustowicz
Journal:  Cell Mol Life Sci       Date:  2002-02       Impact factor: 9.261

3.  Prefrontal dopamine D1 receptors and working memory in schizophrenia.

Authors:  Anissa Abi-Dargham; Osama Mawlawi; Ilise Lombardo; Roberto Gil; Diana Martinez; Yiyun Huang; Dah-Ren Hwang; John Keilp; Lisa Kochan; Ronald Van Heertum; Jack M Gorman; Marc Laruelle
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

4.  Symptom severity and personal functioning among patients with schizophrenia discharged from long-term hospital care into the community.

Authors:  T Trauer
Journal:  Community Ment Health J       Date:  2001-04

Review 5.  Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.

Authors:  A George Awad
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

6.  Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia.

Authors:  Anne Kästner; Sabrina Grube; Ahmed El-Kordi; Beata Stepniak; Heidi Friedrichs; Derya Sargin; Judith Schwitulla; Martin Begemann; Ina Giegling; Kamilla W Miskowiak; Swetlana Sperling; Kathrin Hannke; Anna Ramin; Ralf Heinrich; Olaf Gefeller; Klaus-Armin Nave; Dan Rujescu; Hannelore Ehrenreich
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

7.  Hope and burden among Latino families of adults with schizophrenia.

Authors:  Mercedes Hernandez; Concepción Barrio; Ann-Marie Yamada
Journal:  Fam Process       Date:  2013-07-17

8.  Measurement of quality of life in schizophrenia: a comparison of two scales.

Authors:  Yvette Kusel; Richard Laugharne; Sian Perrington; Jan McKendrick; Deborah Stephenson; J Stockton-Henderson; Madeline Barley; R McCaul; Tom Burns
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-08-29       Impact factor: 4.328

9.  The use of the theory of planned behavior to predict engagement in functional behaviors in schizophrenia.

Authors:  Brent T Mausbach; Raeanne C Moore; Taylor Davine; Veronica Cardenas; Christopher R Bowie; Jennifer Ho; Dilip V Jeste; Thomas L Patterson
Journal:  Psychiatry Res       Date:  2012-09-29       Impact factor: 3.222

10.  Thalamocortical dysconnectivity in schizophrenia.

Authors:  Neil D Woodward; Haleh Karbasforoushan; Stephan Heckers
Journal:  Am J Psychiatry       Date:  2012-10       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.